AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02008396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.
Trial: NCT00211536
Drug: Medtronic MiniMed Implantable Pump Human Recombinant Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
Trial: NCT03055377
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
Trial: NCT04301349
Drug: vaginal dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
Trial: NCT04301349
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two tablets of placebo given 3 hours prior to IUD insertion
Trial: NCT02049385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01243047
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib, Oxaliplatin, Capecitabine
Trial: NCT00768040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily
Trial: NCT01908335
Drug: PEG-IFN-SA /RBV low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Trial: NCT01908335
Drug: PEG-IFN-SA /RBV middle dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Trial: NCT01908335
Drug: PEG-IFN-SA /RBV high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Trial: NCT01908335
Drug: Pegasys /RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Trial: NCT00124696
Drug: Cocaethylene
RxNorm normalized name: Cocaethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00182793
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
Trial: NCT02719028
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
Trial: NCT03854552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT01234142
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
Trial: NCT01234142
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
Trial: NCT03699774
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin is provided as a 10-mg tablet for oral administration
Trial: NCT01716585
Drug: ABT-450/r/ABT-267, ABT-333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Trial: NCT01716585
Drug: Placebo for ABT-450/r/ABT-267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01716585
Drug: Placebo for ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02476864
Drug: Treatment A (adult formulation)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
Trial: NCT02476864
Drug: Treatment B (pediatric formulation)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
Trial: NCT00405756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
Trial: NCT03111810
Drug: AZD4017 and prednisolone
RxNorm normalized name: prednisolone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
Trial: NCT04077567
Drug: TS-152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg,80mg
Trial: NCT00372073
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg bid x 3 days every 2 weeks
Trial: NCT02707120
Drug: PRGF-Endoret
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
Trial: NCT04051320
Drug: Estradiol 2 Mg tablet
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol tablet
Trial: NCT03334682
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dispensation of spironolactone at each visit according to the arm description described above.
Trial: NCT03334682
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
Trial: NCT02159495
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01293357
Drug: LEO 90105
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ointment
Trial: NCT02711891
Drug: Drug, placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
Trial: NCT03639493
Drug: Exforge® tab 10/160mg, Crestor® tab 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
Trial: NCT03639493
Drug: CJ-30060 10/160/20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
Trial: NCT02552537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
Trial: NCT02189239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03429803
Drug: DAY101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 day cycle, oral, once per week
Trial: NCT02242305
Drug: Hyoscine Butylbromide - Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02242305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01598831
Drug: ART-123
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Trial: NCT01598831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
Trial: NCT01381601
Drug: Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
Trial: NCT01724021
Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy
Trial: NCT01724021
Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy
Trial: NCT03023436
Drug: Fluoropyrimidine
RxNorm normalized name: Fluoropyrimidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
Trial: NCT00977691
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide
Trial: NCT03490123
Drug: R1-Total community treatment with azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Trial: NCT03490123
Drug: R2-Total community treatment with azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Trial: NCT03490123
Drug: R3-Total community treatment with azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Trial: NCT03490123
Drug: R2-Total targeted treatment with azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Trial: NCT03490123
Drug: R3-Total targeted treatment with azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Trial: NCT02094339
Drug: opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
Trial: NCT00565721
Drug: Fluciclatide Injection - (AH111585 (F18))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F labelled Cyclic RGD peptide PET agent for injection.
Trial: NCT01591044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 puff bid or 2 puffs bid
Trial: NCT01591044
Drug: R940343 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R343 1mg, 1 puff bid
Trial: NCT01591044
Drug: R940343 2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R343 2mg, 2 puffs bid
Trial: NCT03950505
Drug: Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5\~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
Trial: NCT03600233
Drug: CVM-1118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met.
Trial: NCT06745856
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival, peroperative application of normal saline (NaCl 0.9%)
Trial: NCT00286234
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omacor placebo plus niaspan placebo
Trial: NCT01634087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally
Trial: NCT04003948
Drug: Ibogaine Hydrochloride
RxNorm normalized name: IBOGAINE HYDROCHLORIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
Trial: NCT03356327
Drug: Actitan F
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children
Trial: NCT03356327
Drug: Standard Oral Rehydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral rehydration as suggested by ESPGHAN guidelines
Trial: NCT04118127
Drug: 2mg conventional tablet, once-weekly tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
Trial: NCT02134340
Drug: [I-124]-CPD-1028 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous dose of \[I-124\]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
Trial: NCT00209079
Drug: Gleevec, Taxotere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
Trial: NCT01040000
Drug: NPC-1C/NEO-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
Trial: NCT01639846
Drug: RX-10045
RxNorm normalized name: BARRIER,SENSURA COLOPLAST #10045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
Trial: NCT00160147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03284931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02761486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in matching capsules
Trial: NCT00427089
Drug: Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate
RxNorm normalized name: ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2L gut lavage solution
Trial: NCT01839721
Drug: Bifilact®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
Trial: NCT02119754
Drug: Plurogel PN
RxNorm normalized name: PLUROGEL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04553068
Drug: EVO100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVO100 vaginal gel
Trial: NCT04553068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal gel
Trial: NCT01922479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
Trial: NCT03057314
Drug: Amorphous Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with:~1. ACC tablets, containing 200 mg elemental calcium~2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension
Trial: NCT02790957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of an equal volume of NaCl solution
Trial: NCT04557189
Drug: TAK-951 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-951 placebo-matching SC injection
Trial: NCT00708344
Drug: Irbesartan - Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / irbesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
Trial: NCT00708344
Drug: Irbesartan - Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / irbesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
Trial: NCT02232620
Drug: BBI503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
Trial: NCT01636479
Drug: SAR405838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Trial: NCT04231136
Drug: EAPA115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAPA115
Trial: NCT04231136
Drug: RAPA115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAPA115
Trial: NCT00684229
Drug: general anesthesia followed by opioid analgesia
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sevoflurane general anesthesia and postoperative opioid analgesia
Trial: NCT03011320
Drug: EC1456
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV) bolus dose
Trial: NCT02939326
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04918524
Drug: low molecular weight heparin Enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
Trial: NCT02651311
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
Trial: NCT02651311
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen in ward when more or equal to FLACC scale 4.
Trial: NCT04013555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavored effervescent formulation designed to mimic NAC
Trial: NCT02173769
Drug: Spiriva® Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
Trial: NCT02173769
Drug: Striverdi® Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
Trial: NCT00631514
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os